Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
149
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Pharmacovigilance01:19

Pharmacovigilance

786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PANDA pediatric arousal neural detection architecture.

NPJ digital medicine·2026
Same author

Responsible use of artificial intelligence in peer-reviewed publications in epilepsy.

Epilepsia·2026
Same author

Between Patterns and Predictions: Interpretable Latent EEG Representations for Clinical Insights.

medRxiv : the preprint server for health sciences·2026
Same author

BCGNet: an AI model trained on 600 K hours of sleep data for a novel under-pillow contactless monitoring device.

NPJ digital medicine·2026
Same author

Association between Interictal Spike Rate and Seizure Frequency in a Large Epilepsy Cohort.

medRxiv : the preprint server for health sciences·2026
Same author

Automated Prediction of Glasgow Coma Scale Scores From Unstructured Electronic Health Records Using Natural Language Processing: Development and Validation Study.

Journal of medical Internet research·2026

Related Experiment Video

Updated: Jun 13, 2025

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.8K

Does missing medication acutely change seizure risk? A prospective study.

Daniel M Goldenholz1,2, Joshua C Cheng1,2, Chi-Yuan Chang1,2

  • 1Department of Neurology, Harvard Medical School, Boston, MA.

Medrxiv : the Preprint Server for Health Sciences
|June 12, 2025
PubMed
Summary
This summary is machine-generated.

Missing anti-seizure medication doses does not significantly increase short-term seizure risk in epilepsy patients. This study suggests occasional missed doses may not impact immediate seizure likelihood, though consistent adherence remains important.

Keywords:
forecastmedication adherenceprospectiveseizure

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K

Related Experiment Videos

Last Updated: Jun 13, 2025

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

2.8K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Epilepsy Management

Background:

  • Medication adherence is crucial in epilepsy management, with a common belief that even single missed doses can precipitate seizures.
  • However, robust scientific evidence specifically linking occasional missed anti-seizure medication (ASM) doses to increased short-term seizure risk is limited.

Purpose of the Study:

  • To investigate whether missing individual doses of ASMs elevates the short-term seizure risk in individuals with drug-resistant epilepsy.
  • To provide evidence-based guidance for patients and clinicians regarding the impact of infrequent missed doses.

Main Methods:

  • A 10-month prospective cohort study involving adults with drug-resistant epilepsy or caregivers of pediatric patients.
  • Participants used mobile apps for daily documentation of ASM intake and seizure occurrences.
  • Seizure risk was analyzed using mixed-effects logistic regression, incorporating the "Napkin method" (90-day moving average) to control for baseline seizure frequency.

Main Results:

  • The 90-day moving average of seizure frequency was significantly associated with seizure occurrence (p<0.001).
  • However, missed ASM doses on the preceding day showed no statistically significant relationship with seizure occurrence (p=0.68).
  • This lack of association remained consistent across various time windows and when accounting for medication half-lives, with sensitivity analyses confirming the study's power to detect even small effects.

Conclusions:

  • Long-term medication non-adherence is a significant concern in epilepsy, but this study found no evidence that occasionally missing ASM doses increases short-term seizure risk.
  • Clinicians can reassure patients that infrequent missed doses are unlikely to cause immediate increases in seizure likelihood.
  • Consistent adherence to ASMs should still be encouraged for overall epilepsy management.